期刊文献+

阿加曲班杂质合成研究 被引量:1

Study on the Synthesis of Impurities in Argatroban Anhydrous
下载PDF
导出
摘要 目的探讨阿加曲班起始原料3-甲基-8-喹啉磺酰氯中的异构体杂质来源与合成方法,为阿加曲班的质量控制提供依据和杂质对照品。方法杂质A以5-溴-3-甲基喹啉为起始物,依次进行Buchwald、脱保护基、与亚硝酸盐重氮化及Sandermeyer等反应制得;杂质B以5-溴-2-硝基苯甲醛为起始物,经铁粉还原、关环,再经Buchwald、脱保护基、重氮化及Sandermeyer等反应制得。结果该试验所合成的2个异构体杂质经液相色谱-质谱联用(LC-MS)及氢谱核磁共振(1H-NMR)进行结构确证,与目标化合物结构相符。结论该合成方法简单易行,合成的2个异构体杂质可作为杂质对照品,用于阿加曲班原料药的质量控制。 Objective To investigate the source and synthesis method of isomer impurities in 3-methyl-8-quinoline sulfonyl chloride,the starting material of argatroban anhydrous,and to provide a basis and impurity reference materials for quality control of argatrobananhydrous. Methods The impurity A was prepared from 5-bromo-3-methylquinoline by reaction with Buchwald, off-protectinggroup,diazotization and Sandermeyer. The impurity B was prepared from 5-bromo-2-nitrobenzaldehyde by the reduction with iron powderand closure of the ring, and reaction of Buchwald, off-protecting group, azotization and Sandermeyer. Results The structures of thetwo isomers were confirmed by LC-MS and1 H-NMR, which were consistent with the target compounds. Conclusion The syntheticmethod is simple and feasible. The two synthesized isomer impurities can be used as impurity reference substances for the qualitycontrol of argatroban anhydrous.
作者 黎银波 李剑峰 姚金成 张贵赋 LI Yinbo;LI Jianfeng;YAO Jincheng;ZHANG Guifu(Hunan Center for Drug Evaluation and ADR Monitoring,Changsha,Hunan,China 410013;Hunan Sailong Pharmaceutical Co.,Ltd.,Yueyang,Hunan,China 414200)
出处 《中国药业》 CAS 2019年第5期18-20,共3页 China Pharmaceuticals
关键词 阿加曲班 3-甲基-8-喹啉磺酰氯 异构体杂质 合成方法 argatroban anhydrous 3-methyl-8-quinoline sulfonyl chloride isomer impurity synthesis method
  • 相关文献

参考文献5

二级参考文献64

  • 1王登芹,宋国红,谭洪勇.必存治疗急性脑梗死的疗效观察[J].济宁医学院学报,2006,29(2):63-63. 被引量:13
  • 2饶明俐.《中国脑血管病防治指南》摘要(五)[J].中风与神经疾病杂志,2006,23(3):260-263. 被引量:63
  • 3Daneschvar HL,Daw H.Heparin-induced thrombocytopenia(an overview).Int J Clin Pract,2007;61:130-137
  • 4Lunven C,Gauffeny C,Lecoffre C,et al.Inhibition by Argatroban,a specific thrombin inhibitor,of platelet activation by fibrin clot-associated thrombin.Thromb Haemost.1996;75:154-160
  • 5Berry CN,Girardot C,Lecoffre C,at al.Effects of the synthetic thrombin inhibitor argatroban on fibrin-or clot-incorporatad thrombin:comparison with heparin and recombinant Hirudin.Thromb Haemost,1994;72:381-386
  • 6Jang IK,Cold HK,Ziskind AA,et al.Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition.Circulation,1990;81:219-225
  • 7Sinnsove PR,Simes J,Yusuf S,et al.Direct thrombin iahibiton in acute coronary syndromes:effectin patients undergoing early percutaneous coronary intervention.Eur Heart J JT-European heart journal,2005;26:2396-2403
  • 8Cruz-Conzalez I,Sanchez-Ledesma M,Baron SJ,et al.Efficacy and safety of argatroban with or without glycoprotein Ⅱb/Ⅲa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome.J Thumb Thrombolysis JY-Journal of thrombosis and thrombolysis,2008;25:214-218
  • 9Matthai WH Jr,Hursting MJ,Lewis BE,et al.Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia.Thromb Res,2005;116:121-126
  • 10Lewis BE.Walenga JM.Argatroban in HIT type Ⅱ and acutecoronary syndrome.Pathophysiol Haemost Thromb.2002;32 Suppl 3:46-55

共引文献61

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部